Vaccinex implements 1-for-14 reverse stock split to regain Nasdaq minimum bid price compliance

VACCINEX, INC.

Split effective 5:00 p.m. ET Feb 19, 2024; shares trade split-adjusted from Feb 20.
Ratio 1-for-14, approved by board and stockholders; new CUSIP 918640301.
Complying with $1.00 minimum bid price required by Nasdaq by March 4, 2024.
Fractional shares rounded up; authorized shares unchanged; equity awards adjusted.
Shares continue trading under symbol VCNX; transfer agent is Computershare.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

VACCINEX, INC.: Implemented a 1-for-14 reverse stock split of the Company's issued common stock, effective at 5:00 p.m. Eastern Time on February 19, 2024, via a Certificate of Amendment to the Amended and Restated Certificate of Incorporation (effective 2024-02-19).

Change: charter amendment
Effective: 2024-02-19

Exact text from the filing

On February 14, 2024, Vaccinex, Inc. (the “Company”) filed a Certificate of Amendment (the “Amendment”) to the Company’s Amended and Restated Certificate of Incorporation, as amended, with the Delaware Secretary of State to implement a reverse stock split of the Company’s issued shares of common stock at a ratio of 1-for-14, effective at 5:00 p.m. Eastern Time on Monday February 19, 2024 (the “Reverse Stock Split”), previously approved by the Company’s Board of Directors.

View on SEC.gov

Browse all governance changes →

VACCINEX, INC. filing history →

Source: SEC EDGAR

accession 0001193125-24-037078

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.